 Home > Active Ingredient News > Antitumor Therapy > Lancet Oncol: Intensive chemotherapy before preoperative radiotherapy and chemotherapy for patients with advanced rectal cancer can further significantly improve the prognosis of patients

Lancet Oncol: Intensive chemotherapy before preoperative radiotherapy and chemotherapy for patients with advanced rectal cancer can further significantly improve the prognosis of patients

 Last Update: 2021-05-08
 Source: Internet
 Author: User

Tags

hazard label pictogram

ratio

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Treatment of locally advanced rectal cancer with chemotherapy, radiotherapy, surgery, and adjuvant chemotherapy can control local disease progression, but distant metastasis is still common.

The study is an open-label, randomized phase 3 trial conducted in 35 hospitals in France, recruiting 18-75-year-old newly diagnosed, histologically confirmed, cT3 or cT4 M0 patients with rectal adenocarcinoma (WHO performance status 0-1 points).

PFS and OS

From June 5, 2012 to June 26, 2017, a total of 461 patients were randomly divided into two groups: 231 in the neoadjuvant chemotherapy group and 230 in the standard treatment group.

After a median follow-up of 46.

Adverse events

During neoadjuvant chemotherapy, the most common grade 3-4 adverse events were neutropenia (17%) and diarrhea (11%).

During the entire treatment period, 63 of the 231 patients in the neoadjuvant chemotherapy group (27%) had serious adverse events, while 50 of the 230 patients in the standard treatment group (22%; p=0.

One treatment-related death (sudden death) occurred in the neoadjuvant chemotherapy group, and two treatment-related deaths (1 sudden death and 1 myocardial infarction ) occurred in the standard treatment group .

Myocardial infarction

In summary, for patients with cT3 or cT4 M0 stage rectal cancer, FOLFIRINOX intensive chemotherapy before preoperative radiotherapy can significantly improve their survival prognosis.

For patients with cT3 or cT4 M0 stage rectal cancer, FOLFIRINOX intensive chemotherapy before preoperative radiotherapy can significantly improve their survival prognosis.

Original source:

Thierry Conroy, et al.

org/10.
1016/S1470-2045(21)00079-6" target="_blank" rel="noopener">Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.